YolTech Therapeutics Appoints Dr. Alexandre Moreau to Lead Global Business Development

Shanghai, China – May 28, 2025 – YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced the appointment of Dr. Alexandre Moreau as Strategic Advisor for Global Business Development.

Dr. Moreau will play a leading role in shaping YolTech’s international expansion, advancing global partnerships, and driving strategic transactions as the company accelerates its transition toward a global presence.

Bringing over 35 years of senior leadership experience in the biopharmaceutical industry, Dr. Moreau has held executive positions at Roche, Novartis, Sanofi, Bayer and UCB, where he led enterprise-level strategy, business transformation, and cross-border deals. Prior to joining YolTech, Dr. Moreau served as President of UCB China, overseeing a major restructuring and the divestment of legacy assets through strategic partnerships.

Dr. Moreau holds a Doctorate in Pharmaceutical and Biological Sciences from Rene Descartes University, an MBA from La Sorbonne University in France and graduated from the INSEAD Advanced Management Program and from the General Management Program at Harvard Business School.

Dr. Moreau’s join underscores YolTech’s commitment to building an integrated global organization across science, strategy, and execution as it advances its in vivo genome editing therapies for patients worldwide.